Effect of SARS-COV-2 on human endometrial receptivity

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300068080

Enrollment

Unknown

Registered

2023-02-06

Start date

2022-12-14

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

human endometrial receptivity

Interventions

infected with SARS-Cov-2:NA

controlled :NA

Eligibility

Sex/Gender

Female

Age

22 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Frozen-thawed embryo transfer was/will be done after 9th November, 2022. And the cryopreservation was done before 7th December, 2022. 2. Fresh embryo transfer was done from 9th November 2022 to 7th December 2022. 3. Endometrial receptivity test was/will be done from 14th December, 2022 to 31st December,2023.

Exclusion criteria

Exclusion criteria: 1. Uterine reasons causing embryo implantation failure, such as: adenomyosis, uterine malformation, uterine cavity adhesion, scarred uterus. 2. Medical history of recurrent implantation failures. 3. Diseases negatively affecting embryo implantation, such as SLE, hypertension, diabetes mellitus, insulin resistance and anti-phospholipid syndrome.

Design outcomes

Primary

Measure	Time frame
RNA-seq of human endometrial tissue;Clinical pregnancy rate;embryo implantation rate;rate of early pregnancy loss;	—

Secondary

Measure	Time frame
live birth rate;birthweight;	—

Countries

China

Contacts

Public ContactYanping Li

Xiangya Hospital, Central South University

lisayanping@163.com+86 136 0731 7798

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026